Erasca, Tango Therapeutics Launch Phase 1/2 Trial of Cancer Drug Combination

PUBT · 1d ago
Erasca, Tango Therapeutics Launch Phase 1/2 Trial of Cancer Drug Combination
  • Erasca and Tango Therapeutics opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015 under their collaboration.
  • The trial targets MTAP-deleted pancreatic cancer and RAS-mutant, MTAP-deleted non-small cell lung cancer.
  • Tango sponsors the study, whose dose-escalation phase aims to determine the combination’s maximum tolerated dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040830PRIMZONEFULLFEED9870072) on November 04, 2026, and is solely responsible for the information contained therein.